Overview

Industry Leading TCR Pipeline Targeting Solid Tumors

Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.

SPEAR® T-cell therapies targeting MAGE-A10, MAGE-A4, and AFP are progressing through clinical studies in multiple solid tumors.

The foundation of our TCR therapies is the work we did with NY-ESO SPEAR T-cells, which we transitioned to GSK in 2018, showing responses in two solid tumors and treating more than 90 patients in six different indications.

Our Pipeline

Adaptimmune is developing an industry leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.

Target Trial Indications Phase 1 Trial Phase 2/3
Dose Escalation Expansion
MAGE-A4
SPEARHEAD‑1
(ADP‑A2M4)
Synovial Sarcoma MRCLS
Dose Escalation Phase complete
Expansion Phase complete
Phase 2/3 Phase in progress
SURPASS
(ADP‑A2M4CD8)
Multiple solid tumors**
Dose Escalation Phase in progress
Expansion Phase not started
Phase 2/3 Phase not started
Phase 1 trial
(ADP‑A2M4)
Multiple solid tumors**
Dose Escalation Phase complete
Expansion Phase in progress
Phase 2/3 Phase not started
Radiation sub‑study*
(ADP‑A2M4)
Multiple solid tumors**
Dose Escalation Phase in progress
Expansion Phase not started
Phase 2/3 Phase not started
MAGE-A10
Phase 1 trial
(ADP‑A2M10)
NSCLC Bladder Melanoma Head & neck
Dose Escalation Phase complete
Expansion Phase in progress
Phase 2/3 Phase not started
AFP
Phase 1 trial
(ADP‑A2AFP)
Hepatocellular carcinoma
Dose Escalation Phase in progress
Expansion Phase not started
Phase 2/3 Phase not started

*Site specific protocol amendment with MD Anderson Cancer Center

**Bladder, Melanoma, Head & Neck, Ovarian, NSCLC, Esophageal, Gastric, Synovial sarcoma, MRCLS